Valuation : Exelixis, Inc.

Market Cap 1.42TCr 7.25TCr 1.22TCr 1.15TCr 1.05TCr 1.97TCr 1,36100Cr 1.98TCr 14TCr 5.29TCr 69TCr 5.34TCr 5.23TCr 2,19200Cr P/E 2026 *
17.7x
P/E 2027 * 14.7x
Enterprise Value 1.35TCr 6.87TCr 1.16TCr 1.09TCr 996.87Cr 1.86TCr 1,28900Cr 1.88TCr 13TCr 5.02TCr 65TCr 5.06TCr 4.95TCr 2,07700Cr EV / Sales 2026 *
5.28x
EV / Sales 2027 * 4.35x
Free-Float
98.15%
Yield 2026 *
-
Yield 2027 * -
1 day-0.22%
1 week+0.44%
Current month+0.44%
1 month-1.17%
3 months+12.85%
6 months+29.60%
Current year+14.89%
1 month 131.95
Extreme 131.95
138.3
Current year 104.72
Extreme 104.72
140.56
1 year 98.24
Extreme 98.24
140.56
3 years 50.71
Extreme 50.71
140.56
5 years 40
Extreme 40
140.56
10 years 40
Extreme 40
140.56
Manager TitleAgeSince
Chief Executive Officer 65 22/07/2010
Director of Finance/CFO 58 15/07/2015
Chief Operating Officer 63 01/02/2016
Director TitleAgeSince
Director/Board Member 70 01/02/2004
Director/Board Member 82 01/08/2004
Chairman 77 01/01/1998
Change 5-day change 1-year change 3-year change Capi.($)
-0.22%+0.44% - - 1.45TCr
-0.25%-1.36%+44.08%+102.76% 6.85TCr
-1.09%-6.20%+30.50%+76.56% 6.29TCr
-1.18%+0.47%-12.78%+384.69% 2.81TCr
-1.43%-4.72%+30.17%+9.74% 2.56TCr
-1.76%-6.30%-4.55%-19.75% 2.47TCr
-2.39%-5.19%+17.75%-20.95% 1.98TCr
-1.86%-2.22%+202.03%+353.89% 1.77TCr
-2.57%-5.60%-5.94%+491.55% 1.47TCr
-1.54%-2.88%+52.33%+159.75% 1.45TCr
Average -1.42%-2.00%+39.29%+170.91% 3.07TCr
Weighted average by Cap. -1.17%-2.18%+35.58%+136.78%

Financials

2026 *2027 *
Net sales 255.26Cr 1.3TCr 219.53Cr 207.13Cr 188.69Cr 352.73Cr 24TCr 355.94Cr 2.47TCr 949.4Cr 12TCr 958.56Cr 937.6Cr 39TCr 290.08Cr 1.48TCr 249.46Cr 235.38Cr 214.43Cr 400.84Cr 28TCr 404.48Cr 2.8TCr 1.08TCr 14TCr 1.09TCr 1.07TCr 45TCr
Net income 82Cr 418.32Cr 71Cr 67Cr 61Cr 113.4Cr 7.85TCr 114.43Cr 793.07Cr 305.23Cr 3.98TCr 308.17Cr 301.44Cr 13TCr 101.23Cr 516.03Cr 87Cr 82Cr 75Cr 139.89Cr 9.68TCr 141.16Cr 978.31Cr 376.52Cr 4.91TCr 380.15Cr 371.84Cr 16TCr
Net Debt -74Cr -379.49Cr -64Cr -60Cr -55Cr -102.88Cr -7.12TCr -103.81Cr -719.45Cr -276.89Cr -3.61TCr -279.57Cr -273.45Cr -11TCr -162.27Cr -827.14Cr -139.55Cr -131.67Cr -119.95Cr -224.23Cr -16TCr -226.26Cr -1.57TCr -603.52Cr -7.87TCr -609.34Cr -596.02Cr -25TCr
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Employees
1,077
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
57.43USD
Average target price
53.69USD
Spread / Average Target
-6.52%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!